Kezar Life Sciences, Inc. (KZR): Price and Financial Metrics
KZR Price/Volume Stats
| Current price | $0.57 | 52-week high | $1.32 |
| Prev. close | $0.57 | 52-week low | $0.54 |
| Day low | $0.57 | Volume | 109,500 |
| Day high | $0.60 | Avg. volume | 611,601 |
| 50-day MA | $0.61 | Dividend yield | N/A |
| 200-day MA | $0.78 | Market Cap | 41.71M |
KZR Stock Price Chart Interactive Chart >
Kezar Life Sciences, Inc. (KZR) Company Bio
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Latest KZR News From Around the Web
Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive GrowthIn the labyrinth of the stock market, discovering hidden gems often promises exhilarating prospects. |
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceSOUTH SAN FRANCISCO, Calif., November 21, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL. |
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateSOUTH SAN FRANCISCO, Calif., November 13, 2023--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update |
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., November 03, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 50,000 shares of its common stock with an exercise price of $0.77 per share, the closing price of Kezar’s common stock on November 1, 2023, the gra |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
KZR Price Returns
| 1-mo | -7.08% |
| 3-mo | -12.96% |
| 6-mo | -36.13% |
| 1-year | -55.81% |
| 3-year | -94.14% |
| 5-year | -84.25% |
| YTD | -39.84% |
| 2023 | -86.54% |
| 2022 | -57.89% |
| 2021 | 220.31% |
| 2020 | 30.17% |
| 2019 | -83.01% |
Loading social stream, please wait...